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The World Health Organization’s goal for tuberculosis
(TB) control is to detect 70% of new, smear-positive TB
cases and cure 85% of these cases. The case detection
rate is the number of reported cases per 100,000 persons
per year divided by the estimated incidence rate per
100,000 per year. TB incidence is uncertain and not meas-
ured but estimated; therefore, the case detection rate is
uncertain. This article proposes a new indicator to assess
case detection: the patient diagnostic rate. The patient diag-
nostic rate is the rate at which prevalent cases are detected
by control programs and can be measured as the number of
reported cases per 100,000 persons per year divided by the
prevalence per 100,000. Prevalence can be measured
directly through national prevalence surveys. Conducting
prevalence surveys at 5- to 10-year intervals would allow
countries with high rates of disease to determine their case
detection performance by using the patient diagnostic rate
and determine the effect of control measures.
R
eversing global tuberculosis (TB) incidence by 2015
is included in the Millennium Development Goals (1).
Prevalence and death rates (indicator 23) and the propor-
tion of cases detected and cured under a directly observed
treatment strategy (DOTS) (indicator 24) are used to meas-
ure progress towards this goal. For indicator 24, the World
Health Organization (WHO) has formulated the following
goals: a case detection rate of 70% and a cure rate of 85%
(2,3). If both targets are achieved, the effect on TB trans-
mission will be considerable (3,4). 
WHO defines the cure rate as the proportion of new
cases of smear-positive TB that were cured through treat-
ment; this rate is routinely measured by treatment regis-
ters. The case detection rate is the proportion of incident
smear-positive TB cases detected through a TB program.
The case detection rate is measured as the notification rate
of new cases of smear-positive TB divided by the estimat-
ed incidence rate. 
Incidence is estimated by using various sources of
information (5,6). An important element in these estimates
is the proposed relationship between the incidence of TB
and the annual risk for TB infection. Styblo estimated that,
in the absence of control, a 1% (i.e., 1,000/100,000) annu-
al risk for infection would correspond with an incidence of
new cases of smear-positive TB of approximately 50 per
100,000 (7,8). In other words, in the absence of control
measures, 50 cases would generate 1,000 infections; i.e.,
the average patient with a new case of smear-positive TB
would generate approximately 20 infections over time.
The annual risk for infection is measured imprecisely
through tuberculin surveys; problems include cross-reac-
tions caused by Mycobacterium bovis bacillus Calmette-
Guérin vaccination and environmental mycobacteria. The
relationship between risk for infection and incidence
varies, depending on the quality of the control measures
and the role of HIV infection (9). Deriving incidence from
prevalence and the average duration of disease (6) also
gives uncertain results, in particular because the duration
of disease cannot be measured with precision. Deriving
incidence from the number of TB deaths and estimated TB
case death rates (6) also gives uncertain results because
ascertaining cause of death is incomplete in most countries
with a high rate of TB, and TB case death rates vary, since
they depend on the quality of treatment and are strongly
influenced by HIV co-infection (6). Therefore, incidence
estimates are particularly uncertain in sub-Saharan Africa,
which has the highest per capita TB incidence and preva-
lence of HIV infection in the world (5,6).
To measure the incidence of new cases of smear-posi-
tive TB directly, one would require at least two prevalence
surveys, e.g., 1 year apart, as well as a surveillance mech-
anism to detect incident cases in patients dying or emigrat-
ing out between the first and second survey. Moreover,
correct identification of persons with TB is needed to link
results of the second survey to the first. If the time between
surveys is reduced, this reduces the bias of patients dying
or moving out, but the number of incident cases will be
smaller, reducing precision. Direct measurement is thus
costly and complicated, and no country is currently apply-
ing this method. As a result, the incidence of new cases of
smear-positive TB is uncertain, and TB programs do not
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goal. This problem affects low-income countries with high
rates of TB in particular, since these countries tend to have
inadequate case detection and reporting systems. 
These measurement problems are important because
the effect of TB programs depends on their success in
detecting cases. This article proposes an alternative indica-
tor to measure TB case detection. This indicator does not
directly measure the proportion of cases detected but the
speed at which they are detected. 
New Indicator: Patient Diagnostic Rate
Since the case detection rate is estimated indirectly and
is uncertain, another indicator that can be measured more
directly would be desirable. This indicator is the rate at
which prevalent case-patients are recruited by TB pro-
grams, referred to here as the patient diagnostic rate. In
practice, this indicator can be measured as follows: the
number of newly reported cases (i.e., never treated) of
smear-positive TB per 100,000 population per year (notifi-
cation rate) divided by the prevalence of new cases of
smear-positive TB per 100,000 population. The numerator
is obtained from surveillance data and the denominator
from a prevalence survey. The denominator represents the
population at risk for case detection, the numerator those
actually detected. At present, the proposal is to restrict
patient diagnostic rate to smear-positive cases because
smear microscopy is currently the most widely applied tool
to confirm TB in countries with high rates of disease. The
proposal is restricted to new cases, since this best captures
the effects of case detection. The prevalence of previously
treated TB depends strongly on the cure rate. Patient diag-
nostic rates in countries conducting and reporting a preva-
lence survey during the past decade are presented in the
Table.
A more refined estimate of patient diagnostic rate may
be obtained by stratification for important variables that
are recorded routinely, such as age, sex, urban versus rural
areas, and DOTS versus non-DOTS areas. DOTS areas are
defined as those that have adopted the WHO TB control
strategy. Such stratification may help identify TB priorities
for strengthening case finding and assess the effect of
DOTS. In countries with a high prevalence of HIV infec-
tion, separate estimates for persons with and without HIV
infection indicate differences in the patient diagnostic rate
and death rates between TB patients with and without HIV
co-infection (6). 
Patient Diagnostic Rate, Case Detection 
Rate, and Program Effect
The quantitative relationship between the case detec-
tion rate, patient diagnostic rate, and expected program
effect depends on the way we conceive case detection.
Two approaches have been used in the past, perhaps best
explained with the models of Styblo (model 1) (2,3) and
Dye et al. (model 2) (4).
Model 1 assumes that cases are either detected after an
average of 4 months or not at all (2,3). Patients whose
cases are not detected either die or self-cure after an aver-
age of 2 years. Self-cure refers to patients reverting to
latent infection without being treated. In model 2 (4), cases
are detected at a certain rate (patient diagnostic rate), and
the patients die or self-cure at a certain rate. The proportion
of cases detected in model 2 thus depends on the relative
size of these two rates: the larger the patient diagnostic
rate, the larger the case detection rate and the shorter the
average delay. As a result of these different assumptions,
the same case detection rate of 70% is associated with a
larger patient diagnostic rate and a larger impact on TB
prevalence in model 2 than in model 1 (Appendix). In the
absence of HIV infection, a case detection rate of at least
70% corresponds with a patient diagnostic rate of at least
0.84 per person-year in model 1 and a patient diagnostic
rate of at least 1.17 per person-year in model 2.
How do these model targets compare with values of
patient diagnostic rates we observe in the real world? A
rough, indirect estimate of patient diagnostic rate in the
Netherlands is 2.5 per person-year (Appendix). Of more
relevance may be the direct estimates in countries with
high rates of TB (Table): the patient diagnostic rate was
0.24 in China, 0.43 in Korea, and 0.51 in the Philippines.
These three countries did not meet the goal for case detec-
tion by models 1 or 2. 
For the patient diagnostic rate to be a useful indicator,
the best reporting rate should be obtained. For instance, if
general hospitals in China, or the private sector in the
Philippines and Korea, fail to notify the patients they treat,
the patient diagnostic rate will be underestimated (the
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Table. The patient diagnostic rate in China, Philippines, and Korea
a,b
  Notification rate smear- 
TB per 100,000 
Prevalence rate smear- 
TB per 100,000  PDR  Ref 
China, 2000  17  72  0.24  10,11 
Philippines, 1997  118  229  0.51  12,13 
Korea, 1995  26  60  0.43  14,15 
aTB, tuberculosis; , postive; PDR,
 patient diagnostic rate; ref, reference number.
bIn the Philippines, total prevalence was 310/100,000. Of 50 cases with drug susceptibility results and known treatment history, 37 (74%) had not been 
previously treated. The assumption was that 74% of prevalent smear-positive patients had not been previously treated. In Korea, total prevalence was 
93/100,000. The prevalence of new smear-positive TB was obtained from the unpublished survey report. same limitation applies to the case detection rate).
Therefore, the use of patient diagnostic rate is not an alter-
native to a good reporting system but supports the devel-
opment of such a system. If the notification system detects
most cases (e.g., with a patient diagnostic rate exceeding
the goal of model 2 of 1.17), then reporting data may be
used exclusively to monitor trends, as is done in countries
with low rates of disease.
Limitation of the Patient Diagnostic Rate
A limitation of the patient diagnostic rate is that meas-
uring TB prevalence is complicated and costly with the
current standard methods, which require the use of mobile
chest radiograph equipment as a screening tool. However,
this limitation can be overcome. High standard prevalence
surveys have been shown to be feasible (Table). Moreover,
their cost represents a small proportion of the cost of con-
trol programs. TB control programs in the 22 countries
with high rates of the disease annually cost an estimated
U.S. $940 million, approximately half of which is within
the TB program budget, while the other half represents
health infrastructure costs (16). Twenty-two national sur-
veys, performed with current standard methods once every
5–10 years, would cost approximately U.S. $25–$50 mil-
lion in total, i.e., <U.S. $10 million per year. This cost rep-
resents at most 1% of the cost of TB control programs. 
Nevertheless, new survey methods, using other diag-
nostic algorithms or new diagnostic methods, that do not
require mobile chest radiographs would be beneficial.
They would promote the measurement of TB case detec-
tion and program effect in the 22 countries with high rates
of disease and in other high incidence-countries with lim-
ited resources, especially Africa.
Conclusion
The patient diagnostic rate is a measurable indicator for
detecting patients with previously untreated cases of
smear-positive TB. The expected effect of a TB control
program on transmission increases with an increasing
value of this indicator. A patient diagnostic rate of >0.84
would correspond to the original WHO goal proposed by
Styblo of detecting >70% of incident cases. Apatient diag-
nostic rate of >1.17 would meet the goal of 70% case
detection as used by Dye et al. to project the effect of the
DOTS strategy (4). On the basis of further evidence about
patient diagnostic rates and associated TB program impact,
a revised goal may be formulated in the future. 
While monitoring performance is extremely useful in
the short-term, monitoring effects, or at least the trend of
TB prevalence, is most important in the medium- and
long-term. Programs aimed at reducing TB prevelance can
assess whether the decrease is occurring through reporting
rates, if case detection is good, or by carrying out preva-
lence surveys every 5–10 years, if the completeness of
case detection varies or is uncertain. Prevalence surveys
would provide direct information on indicator 23 for meas-
uring progress towards meeting the Millennium
Development Goals (1). Monitoring effect through preva-
lence surveys allows the patient diagnostic rate to be meas-
ured and the risk factors for nondetection to be identified
by the health service. Developing new diagnostic methods,
obviating the need for chest radiographs, would be
extremely helpful for such surveys. Monitoring TB is rec-
ommended through prevalence surveys in countries with
high rates of disease until reporting rates have been shown
to provide sufficient information on TB trends in that par-
ticular setting.
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Appendix
Model 1
Model 1, developed by Styblo (1,2), is presented in Appendix
Figure 1. The case detection rate in model 1 is not a rate but a
ratio: it does not reflect the speed at which cases are detected, but
the proportion of incident cases detected. Model 1 assumed that,
in the absence of treatment, the duration of the infectious period
is 2 years. Each new self-reporting case was assumed to be
detected after an average of 4 months. The case detection rate
(the proportion of new cases detected) would thus directly deter-
mine the prevalence of new smear-positive tuberculosis (TB).
Since the interest of this article is to assess case detection, the
left part of Figure 1 is concentrated on, which is relevant for the
prevalence of new cases of smear-positive TB only (Appendix
Figure 2A). When Appendix Figure 2A and the assumptions
above are used, the following expressions can be derived:
Pnew = Inew pyr–1 ⋅ CDR ⋅ 0.33 pyr + Inew pyr–1 ⋅ (1 – CDR) ⋅ 2pyr =
= 2 ⋅ I new ⋅ (1 – 0.83 CDR) (1)
Where 
Pnew = prevalence ratio of new (i.e., never treated) cases of
smear-positive TB
Inew = incidence rate (pyr–1) of new smear-positive TB
CDR= case detection rate = proportion of cases detected
By definition:
Nnew = CDR ⋅ Inew (pyr–1) (2)
Where
Nnew = notification rate (pyr–1) of new cases of smear-positive
TB
and thus
Nnew / Pnew = 0.5 pyr–1 ⋅ CDR / (1 – 0.83CDR) (3)
Model 2
Model 2 was used by Dye et al. and assumes that incident
cases are at risk for case detection and for death or self-cure
(Appendix Figure 2B) (modified from [3]). Asimilar approach is
used by others (4). If the rates in model 2 were constant (i.e.,
independent of time since onset of disease), the combined rate of
death and self-cure would be 0.5 pyr–1 if the average duration of
disease were 2 years in the absence of case detection. Indeed,
Dye et al. assumed a rate of death of 0.3 pyr–1 and a rate of self-
cure of 0.2 pyr–1 (3). The patient diagnostic rate (PDR) is defined
as the rate at which patients are diagnosed. The proportion of
incident cases detected (the case detection rate [CDR]) therefore
equals:
CDR = PDR pyr–1/(PDR + 0.5) pyr–1 (4)
Which is equivalent to:
PDR (pyr–1) = 0.5 pyr–1 ⋅ CDR/(1 – CDR) (5)
Since PDR may be estimated as Nnew/Pnew this can also be pre-
sented as:
Nnew/Pnew = 0.5 pyr–1 CDR/(1 – CDR) (6)
And since Nnew = CDR ⋅ Inew:
Pnew = 2 pyr ⋅ Inew pyr–1 ⋅ (1 – CDR) (7)
To assess to what extent a constant rate of detection (assumed
by model 2) is supported by data on delay before diagnosis, we
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Appendix Figure 1. Model 1, used by Styblo, of tuberculosis case
detection and treatment outcome in tuberculosis control program.
Prevalent cases are those within dotted line.used data from the Netherlands Tuberculosis Register. From 1996
to 2002, a total of 468 new cases of smear-positive TB were diag-
nosed among the Dutch; these cases were found through passive
case finding and had a recorded delay in treatment. Person-weeks
at risk for detection were estimated by week since onset and used
as the denominator for the rate of detection. Patient diagnostic
rate was first estimated ignoring death rates and self-cure, and
then by assuming an average rate of death and self cure of 0.5
pyr–1.
Results
The relationship between case detection rate and patient diag-
nostic rate according to models 1 and 2 is presented in Appendix
Figure 3. In both models, a one-to-one, nonlinear relationship
exists between case detection rate and patient diagnostic rate:
patient diagnostic rate increases with increasing case detection
rates. This increase is steepest in model 2.
However, the same case detection rate in models 1 and 2 rep-
resent different effects on TB prevalence. For instance, a case
detection rate of 70% according to model 1 (which is the basis of
the current WHO goal) corresponds with a reduction of the
prevalence of new cases of smear-positive TB of 58%. According
to model 2, to achieve a 58% reduction of this prevalence, a case
detection rate of 58% is required (Appendix Figure 4). If the goal
is to reduce the prevalence of new cases of smear-positive TB by
58%, patient diagnostic rate would need to be 0.84, according to
model 1, and 0.69 according to model 2. However, if the case
detection rate goal is maintained at 70% while using model 2 (as
was done by Dye et al. [3]), the corresponding patient diagnostic
rate would be 1.17. Achieving this goal would be associated with
a higher effect on TB prevalence than achieving the goal of 0.84
suggested by model 1.
In model 2, the patient diagnostic rate and the combined rate
of death and self-cure were assumed to be constant, i.e., inde-
pendent of time since diagnosis. The rate of detection based on
reported patient’s and doctor’s delay in the Netherlands is pre-
sented in Appendix Figure 5. The rates of detection, first by
ignoring and then by taking into account death and self-cure,
were approximately 3.0 and 2.5 per person-year, respectively.
The last figure corresponds with a case detection rate of 84%,
according to expression (4). Patient diagnostic rate was lower
during the first 4 weeks of disease. During the first 4 weeks, the
rate increased approximately linearly from 0 to 2.5 per person-
year. 
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Appendix Figure 2. Models 1 and 2 on tuberculosis case detection.
A) the arrows depict proportions of cases moving from one com-
partment to another. B) Model 2, used by Dye et al. with rate of
case detection (PDR). The arrows depict rates. 
A
B Appendix Figure 3. Relationship of case detection rate (CDR) and
patient diagnostic rate (PDR) according to model 1 and model 2. 
Appendix Figure 4. Reduction of prevalence of new smear-positive
tuberculosis depending on the case detection rate (CDR) accord-
ing to model 1 and model 2.Appendix References
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Appendix Figure 5. Estimates of the patient diagnostic rate (PDR)
in the Netherlands, depending on the duration of symptoms.
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